TS expression predicts postoperative recurrence in adenocarcinoma of the lung

Shimokawa, Hidehiko; Uramoto, Hidetaka; Onitsuka, Takamitsu; Iwata, Teruo; Nakagawa, Makoto; Ono, Kenji; Hanagiri, Takeshi

doi:10.1016/j.lungcan.2010.08.024

Cited by 25 publications

(21 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Twenty-five and 6 cases had hematogenous (brain = 9, lung = 10, bone = 5, and adrenal metastasis = 1) and locoregional (lymph node metastasis = 4, and pleural dissemination = 2) recurrences, respectively. Two subjects had recurrent tumors in both the brain and bone, brain and adrenal gland, and bone and lymph nodes, respectively [16]. …”

Section: Methodsmentioning

confidence: 99%

Epidermal Growth Factor Receptor-GEP100-Arf6 Axis Affects the Prognosis of Lung Adenocarcinoma

et al. 2014

Self Cite

View full text Add to dashboard Cite

The overexpression of Arf6 and GEP100 is responsible for the invasive activity that is crucial for the activation of the epidermal growth factor receptor (EGFR) signaling pathways in human cancer. However, whether or not the expression of the EGFR-GEP100-Arf6 axis can be used as a biomarker for the prognosis of lung cancer has yet to be fully determined. Tumor specimens were collected from 182 patients who underwent a complete resection for lung adenocarcinoma. We analyzed phospho-EGFR (p-EGFR), GEP100, and Arf6 expression levels in the primary tumor by immunohistochemical analysis. The expression of p-EGFR, GEP100, and Arf6 was observed in 65 (35.7%), 95 (52.2%), and 20 (11.0%) patients, respectively. Significant associations between p-EGFR and GEP100 expression and vessel invasion were identified. The expression of these individual molecules was not associated with any statistically significant differences in survival. However, triple positive expression of p-EGFR, GEP100, and Arf6 was significantly associated with an increased risk of death based on the multivariate analysis. The EGFR-GEP100-Arf6 axis affected the prognosis of patients with primary lung adenocarcinoma. The combination of p-EGFR, GEP100, and Arf6 staining can predict the prognosis of patients after surgery.

show abstract

Section: Methodsmentioning

confidence: 99%

Epidermal Growth Factor Receptor-GEP100-Arf6 Axis Affects the Prognosis of Lung Adenocarcinoma

et al. 2014

Self Cite

View full text Add to dashboard Cite

show abstract

“…A total of 13 HRs for PFS [17,[19][20][21][29][30][31][32][33]35,37,41,42] and 20 HRs for OS [7,14,16-18,21-23,29-32, 34,36,38-42] were available for pooled HR calculation. Meta-analysis by a random effect model showed that patients with low TS protein expression had significantly longer OS than those with high TS expres-sion (pooled HR, 0.51; 95% CI, 0.36-0.73) (Fig.…”

Section: Meta-analysismentioning

confidence: 99%

Prognostic and predictive significance of thymidylate synthase protein expression in non-small cell lung cancer: A systematic review and meta-analysis

Liu

Xiang

et al. 2015

CBM

View full text Add to dashboard Cite

show abstract

“…The primary antibody used was a mouse monoclonal antibody against human IGFR1 (3C8B1; Abcam, Cambridge, MA, USA) (12), diluted 1:500 in PBS and incubated for 18 h at 4˚C. Thereafter, IHC staining was performed by the labeled polymer method (Histofine Simple Stain MAX-PO kit; Nichirei, Tokyo, Japan) according to the manufacturer's instructions (13,14). The positive and negative controls were processed using primary lung squamous cell carcinoma specimens expressing IGFR1 and by the exclusion of the primary antibody, respectively.…”

Section: Immunohistochemical Staining and Evaluation For Igfr1mentioning

confidence: 99%

Insulin-like growth factor receptor-1 expression predicts postoperative recurrence in adenocarcinoma of the lung

Nakagawa

Uramoto

Shimokawa

et al. 2011

Experimental and Therapeutic Medicine

Self Cite

View full text Add to dashboard Cite

Abstract. Not all patients with lung cancer require postoperative adjuvant chemotherapy after a complete resection. However, no useful markers exist for either selecting appropriate candidates or for predicting clinical recurrence. The purpose of the present study was to clarify the clinical role of insulin-like growth factor receptor-1 (IGFR1) in lung adenocarcinoma. Tumor specimens were collected from 182 patients who underwent a complete resection for adenocarcinoma of the lung. The expression of IGFR1 was evaluated by immunohistochemistry. The genetic status of the epidermal growth factor receptor (EGFR) and K-ras genes was also investigated by PCR-based analyses. Immunohistochemistry and real-time PCR assays were used to evaluate the MET gene association with tyrosine phosphorylation and hepatocyte growth factor (HGF) status, and amplification, respectively. Positive expression of IGFR1 was detected in 43 (23.6%) of the 182 cases. A positive IGFR1 expression was also identified in 12 (42.9%) and 31 (20.1%) of the patients with and without recurrence, respectively (p=0.009). Logistic regression models indicated that positive staining for IGFR1 expression was an independent factor associated with tumor recurrence. IGFR1 expression was associated with a poorer disease-free survival (DFS). Multivariate analysis demonstrated positive IGFR1 expression to be independently associated with an increased risk for poor DFS. The tumors appearing positive for IGFR1 were more frequent among those with K-ras mutations when compared with the wild-type group. IGFR1 expression was associated with reduced DFS correlating with postoperative recurrence. Therefore, the expression status of IGFR1 can be a candidate surrogate marker to select patients who may benefit from adjuvant chemotherapy. IntroductionLung cancer is the leading cause of cancer-related death in the world (1). The incidence of adenocarcinoma, one of the major histological subtypes of non-small cell lung cancer (NSCLC), is increasing (2). The prognosis is dismal as the 5-year survival is only approximately 50%, even in patients who achieve complete surgical resection (3). This suggests that occult metastases are present at the time of surgical intervention. As a consequence, adjuvant chemotherapy is required (4). However, the 5-year survival rate of patients with resected stage IB NSCLC is 74% without adjuvant chemotherapy, suggesting that not all patients require chemotherapy after a complete resection (5). Therefore, it is necessary to identify patients who may benefit the most from post-operative adjuvant chemotherapy to, not only precisely select the patients who require additional treatment, but also to prevent the occurrence of adverse events in patients who do not require treatment (4). Therefore, it is important to evaluate the biological and molecular characteristics of lung adenocarcinoma to identify the factors related to recurrence following surgery. However, there are currently no useful markers that predict clinical recurrence.Insulin-like growth fa...

show abstract

TS expression predicts postoperative recurrence in adenocarcinoma of the lung

Cited by 25 publications

References 27 publications

Epidermal Growth Factor Receptor-GEP100-Arf6 Axis Affects the Prognosis of Lung Adenocarcinoma

Epidermal Growth Factor Receptor-GEP100-Arf6 Axis Affects the Prognosis of Lung Adenocarcinoma

Prognostic and predictive significance of thymidylate synthase protein expression in non-small cell lung cancer: A systematic review and meta-analysis

Insulin-like growth factor receptor-1 expression predicts postoperative recurrence in adenocarcinoma of the lung

Contact Info

Product

Resources

About